Skip to main content

CAPITAL FUND MANAGEMENT S.A.

Position in NBIX — Neurocrine Biosciences Inc

CIK 1323645 PARIS, I0

Position in NBIX

as of Mar 31, 2026 · filed May 14, 2026
Position Value
$19,712,387
+$8,348,259 QoQ
Shares Held
149,631
+86.7% QoQ
Ownership
0.149%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
13 quarters on record
Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Common Shares in NBIX Over Time

Shares Held

Position Value (USD)

Derivatives in NBIX

reported options exposure · as of Mar 31, 2020
CallValue
$657,780
CallShares
7,600
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

CAPITAL FUND MANAGEMENT S.A. holds $92,308,096 across 12 Drug Manufacturers - Specialty & Generic names. NBIX ranks #3 (21.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
3 NBIX
Neurocrine Biosciences Inc
This page
149,631 $19,712,387

All Filings in NBIX

Export CSV
14 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $19,712,387 149,631
2025-12-31 $11,364,128 80,125
2025-09-30 $17,365,567 123,704
2025-06-30 $25,594,003 203,628
2025-03-31 $19,425,894 175,641
2024-12-31 $14,267,526 104,524
2024-09-30 $12,855,325 111,572
2024-06-30 $7,840,444 56,951
2021-03-31 $5,860,868 60,266
2020-12-31 $1,903,293 19,857
2020-09-30 $2,179,658 22,667
2020-06-30 $2,359,236 19,338
2020-03-31 $2,046,301 23,643
2020-03-31 $657,780 7,600